The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®)

Isavuconazole: is there a need for a new antifungal?

(2017) Oliver A. Cornely   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens

(2017) J. P. Adler-Moore et al.   JOURNAL OF LIPOSOME RESEARCH

Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions

(2016) Neil R. H. Stone et al.   DRUGS

Comparison between liposomal formulations of amphotericin B

(2016) Jill P Adler-Moore et al.   MEDICAL MYCOLOGY

Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice

(2014) J. A. Olson et al.   MEDICAL MYCOLOGY

Exserohilum Infections Associated with Contaminated Steroid Injections

(2013) Jana M. Ritter et al.   AMERICAN JOURNAL OF PATHOLOGY

Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis

(2010) J. M. Lestner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Erroneous determination of hyperphosphatemia (‘pseudohyperphosphatemia’) in sera of patients that have been treated with liposomal amphotericin B (AmBisome)

(2010) Gerard M. Jensen et al.   CLINICA CHIMICA ACTA

Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India

(2010) Shyam Sundar et al.   NEW ENGLAND JOURNAL OF MEDICINE